Pravastatin cholesterol lowering intervention
systematic review meta-analysis network meta-analysis
 

Lipostat - Pravasin - Pravacol - Selektine - Elisor - Pravachol - Mevalotin - Prareduct - Lipemol - CS514 - CS 514 - CS-514 - Bristacol - Vasten - SQ31000 - SQ 31000 - SQ-31000 - RMS431 - RMS 431 - RMS-431 - Liplat - Eptastatin - Pravastatin      

Select             pdf
Filter

  • Group by...
Trial Studied trt Control trt patientstagsROB Trial resultAll cause deathstroke (fatal and non fatal)

acute coronary syndrome  

PACT, 2004     pravastatinplaceboacute coronary syndrome early initiation Low risk of bias suggesting-31%-21%
LAMIL, 1997   pravastatinplaceboacute coronary syndrome early initiation Low risk of bias negative
PAIS, 2001   pravastatinplaceboacute coronary syndrome early initiation Low risk of bias negative
RECIFE, 1999     pravastatinplaceboacute coronary syndrome early initiation Low risk of bias negative
PTT, 2002   pravastatinusual careacute coronary syndrome early initiation Exploratory suggesting
L-CAD, 2000     pravastatinusual careacute coronary syndrome early initiation Exploratory suggesting-20%

atrial fibrillation  

Tveit, 2004     pravastatincontrolExploratory negative

cardiovascular prevention  

FAST Fukuoka pravastatin, 2002     pravastatincontrolprimary preventionExploratory -
MEGA, 2006        NCTpravastatincontrolprimary preventionRisk of bias suggesting-29%-17%
PROSPER diabetic (sub group), 2002     pravastatinplacebodiabetic patients secondary prevention Low risk of bias negative
PHYLLIS, 2004     pravastatinplacebodiabetic cerebral vascular disease hypertensive patients Exploratory -
LIPID (diabetic sub group), 1998     pravastatinplacebodiabetic patients secondary prevention Low risk of bias negative
PREVEND IT, 2004     pravastatinplaceborelated disease kidney diseases Low risk of bias negative
CARE (diabetic sub group), 1998     pravastatinplacebodiabetic patients secondary prevention Exploratory suggesting-15%
PROSPER (primary prevention subgroup), 2002     pravastatinplaceboprimary prevention elderly Exploratory negative-2%3%
WOSCOPS (diabetic sub group), 1996     pravastatinplacebodiabetic patients primary prevention Low risk of bias -
KAPS, 1995     pravastatinplaceboprimary preventionExploratory negative-25%
PROSPER, 2002   pravastatinplacebosecondary prevention elderly Low risk of bias conclusive -2%4%
ALLHAT (women subgroup) , 2002     PravastatinplacebowomenExploratory negative-2%
PLAC I, 1995     pravastatinplacebosecondary preventionExploratory suggesting-35%-100%
PLAC II, 1995     pravastatinplacebosecondary preventionExploratory negative
PACT, 2004     pravastatinplacebosecondary preventionLow risk of bias negative-36%
LIPID, 1998         pravastatinplacebosecondary preventionLow risk of bias conclusive-22%-17%
CARE, 1996       pravastatinplacebosecondary preventionLow risk of bias conclusive-8%-31%
WOSCOPS, 1995     pravastatinplaceboprimary preventionLow risk of bias conclusive-22%-10%
LAMIL, 1997   pravastatinplaceboacute coronary syndrome early initiation Low risk of bias negative
RECIFE, 1999     pravastatinplaceboacute coronary syndrome early initiation Low risk of bias negative
PAIS, 2001   pravastatinplaceboacute coronary syndrome early initiation Low risk of bias negative
MEGA (women subgroup) , 2006     PravastatinplacebowomenExploratory suggesting-42%
PACT, 2004     pravastatinplaceboacute coronary syndrome early initiation Low risk of bias suggesting-31%-21%
REGRESS, 1995       pravastatinplacebosecondary preventionExploratory suggesting-40%
PMSG, 1993   pravastatinplaceboprimary preventionExploratory negative-100%
CAIUS, 1996     pravastatinplaceboprimary prevention cerebral vascular disease Exploratory negative
CARE (elderly subgroup), 1998     Pravastatinplaceboelderly elderly Low risk of bias suggesting-28%-38%
LIPID (elderly sub group), 2001     Pravastatinplaceboelderly elderly Low risk of bias suggesting-20%-11%
PLAC I (elderly sub group), 1995     Pravastatinplaceboelderly elderly Low risk of bias negative-38%-100%
REGRESS (elderly subgroup), 1995     Pravastatinplaceboelderly elderly Low risk of bias negative-16%
ALLHAT, 2002      NCTpravastatinusual careat risk hypertensive hypertensive patients Risk of bias negative-1%-9%
GISSI P (diabetic sub group), 2000   pravastatinusual carediabetic patients secondary prevention Exploratory -
ALLHAT-LLT (diabetic sub group), 2002     pravastatinusual carediabetic patients secondary prevention Exploratory negative3%
PTT, 2002   pravastatinusual careacute coronary syndrome early initiation Exploratory suggesting
GISSI Prevenzione, 2000     pravastatinusual caresecondary preventionRisk of bias negative-18%5%
L-CAD, 2000     pravastatinusual careacute coronary syndrome early initiation Exploratory suggesting-20%
KLIS, 2000   pravastatinusual careprimary preventionRisk of bias -
PROVE IT TIMI 22 (diabetic sub group), 2006     pravastatin high dosepravastatindiabetic patients secondary prevention Low risk of bias -

diabetes type 2  

PROSPER diabetic (sub group), 2002     pravastatinplacebodiabetic patients secondary prevention Low risk of bias negative
LIPID (diabetic sub group), 1998     pravastatinplacebodiabetic patients secondary prevention Low risk of bias negative
CARE (diabetic sub group), 1998     pravastatinplacebodiabetic patients secondary prevention Exploratory suggesting-15%
WOSCOPS (diabetic sub group), 1996     pravastatinplacebodiabetic patients primary prevention Low risk of bias -
GISSI P (diabetic sub group), 2000   pravastatinusual carediabetic patients secondary prevention Exploratory -
ALLHAT-LLT (diabetic sub group), 2002     pravastatinusual carediabetic patients secondary prevention Exploratory negative3%
PROVE IT TIMI 22 (diabetic sub group), 2006     pravastatin high dosepravastatindiabetic patients secondary prevention Low risk of bias -

percutaneous coronary intervention  

PREDICT, 1997     pravastatinplaceboLow risk of bias negative301%∞%

post myocardial infarction  

LIPID, 1998         pravastatinplacebosecondary preventionLow risk of bias conclusive-22%-17%
PACT, 2004     pravastatinplacebosecondary preventionLow risk of bias negative-36%
CARE, 1996       pravastatinplacebosecondary preventionLow risk of bias conclusive-8%-31%



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons